Report Detail
Global Indolent Lymphoma Treatment Market Insights, Forecast to 2025
- RnM2932014 |
- 18 February, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
The global Indolent Lymphoma Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Indolent Lymphoma Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Indolent Lymphoma Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Indolent Lymphoma Treatment in these regions.
This research report categorizes the global Indolent Lymphoma Treatment market by top players/brands, region, type and end user. This report also studies the global Indolent Lymphoma Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Juno Therapeutics Inc.
MedImmune, LLC
Market size by Product
BI-836826
ALT-803
BMS-986016
CC-122
Others
Market size by End User
Hospital
Clinic
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Indolent Lymphoma Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Indolent Lymphoma Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Indolent Lymphoma Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Indolent Lymphoma Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Indolent Lymphoma Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Indolent Lymphoma Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Indolent Lymphoma Treatment Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by Product
- 1.4.2 BI-836826
- 1.4.3 ALT-803
- 1.4.4 BMS-986016
- 1.4.5 CC-122
- 1.4.6 Others
- 1.5 Market by End User
- 1.5.1 Global Indolent Lymphoma Treatment Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Indolent Lymphoma Treatment Market Size
- 2.1.1 Global Indolent Lymphoma Treatment Revenue 2014-2025
- 2.1.2 Global Indolent Lymphoma Treatment Sales 2014-2025
- 2.2 Indolent Lymphoma Treatment Growth Rate by Regions
- 2.2.1 Global Indolent Lymphoma Treatment Sales by Regions
- 2.2.2 Global Indolent Lymphoma Treatment Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Indolent Lymphoma Treatment Sales by Manufacturers
- 3.1.1 Indolent Lymphoma Treatment Sales by Manufacturers
- 3.1.2 Indolent Lymphoma Treatment Sales Market Share by Manufacturers
- 3.1.3 Global Indolent Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Indolent Lymphoma Treatment Revenue by Manufacturers
- 3.2.1 Indolent Lymphoma Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Indolent Lymphoma Treatment Revenue Share by Manufacturers (2014-2019)
- 3.3 Indolent Lymphoma Treatment Price by Manufacturers
- 3.4 Indolent Lymphoma Treatment Manufacturing Base Distribution, Product Types
- 3.4.1 Indolent Lymphoma Treatment Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Indolent Lymphoma Treatment Product Type
- 3.4.3 Date of International Manufacturers Enter into Indolent Lymphoma Treatment Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Indolent Lymphoma Treatment Sales by Product
- 4.2 Global Indolent Lymphoma Treatment Revenue by Product
- 4.3 Indolent Lymphoma Treatment Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Indolent Lymphoma Treatment Breakdown Data by End User
6 North America
- 6.1 North America Indolent Lymphoma Treatment by Countries
- 6.1.1 North America Indolent Lymphoma Treatment Sales by Countries
- 6.1.2 North America Indolent Lymphoma Treatment Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Indolent Lymphoma Treatment by Product
- 6.3 North America Indolent Lymphoma Treatment by End User
7 Europe
- 7.1 Europe Indolent Lymphoma Treatment by Countries
- 7.1.1 Europe Indolent Lymphoma Treatment Sales by Countries
- 7.1.2 Europe Indolent Lymphoma Treatment Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Indolent Lymphoma Treatment by Product
- 7.3 Europe Indolent Lymphoma Treatment by End User
8 Asia Pacific
- 8.1 Asia Pacific Indolent Lymphoma Treatment by Countries
- 8.1.1 Asia Pacific Indolent Lymphoma Treatment Sales by Countries
- 8.1.2 Asia Pacific Indolent Lymphoma Treatment Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Indolent Lymphoma Treatment by Product
- 8.3 Asia Pacific Indolent Lymphoma Treatment by End User
9 Central & South America
- 9.1 Central & South America Indolent Lymphoma Treatment by Countries
- 9.1.1 Central & South America Indolent Lymphoma Treatment Sales by Countries
- 9.1.2 Central & South America Indolent Lymphoma Treatment Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Indolent Lymphoma Treatment by Product
- 9.3 Central & South America Indolent Lymphoma Treatment by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Indolent Lymphoma Treatment by Countries
- 10.1.1 Middle East and Africa Indolent Lymphoma Treatment Sales by Countries
- 10.1.2 Middle East and Africa Indolent Lymphoma Treatment Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Indolent Lymphoma Treatment by Product
- 10.3 Middle East and Africa Indolent Lymphoma Treatment by End User
11 Company Profiles
- 11.1 Altor BioScience Corporation
- 11.1.1 Altor BioScience Corporation Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Altor BioScience Corporation Indolent Lymphoma Treatment Products Offered
- 11.1.5 Altor BioScience Corporation Recent Development
- 11.2 Amgen Inc.
- 11.2.1 Amgen Inc. Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Amgen Inc. Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Amgen Inc. Indolent Lymphoma Treatment Products Offered
- 11.2.5 Amgen Inc. Recent Development
- 11.3 Astellas Pharma Inc.
- 11.3.1 Astellas Pharma Inc. Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Astellas Pharma Inc. Indolent Lymphoma Treatment Products Offered
- 11.3.5 Astellas Pharma Inc. Recent Development
- 11.4 Bayer AG
- 11.4.1 Bayer AG Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Bayer AG Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Bayer AG Indolent Lymphoma Treatment Products Offered
- 11.4.5 Bayer AG Recent Development
- 11.5 Boehringer Ingelheim GmbH
- 11.5.1 Boehringer Ingelheim GmbH Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Products Offered
- 11.5.5 Boehringer Ingelheim GmbH Recent Development
- 11.6 Bristol-Myers Squibb Company
- 11.6.1 Bristol-Myers Squibb Company Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Products Offered
- 11.6.5 Bristol-Myers Squibb Company Recent Development
- 11.7 Celgene Corporation
- 11.7.1 Celgene Corporation Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Celgene Corporation Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Celgene Corporation Indolent Lymphoma Treatment Products Offered
- 11.7.5 Celgene Corporation Recent Development
- 11.8 Eli Lilly and Company
- 11.8.1 Eli Lilly and Company Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Eli Lilly and Company Indolent Lymphoma Treatment Products Offered
- 11.8.5 Eli Lilly and Company Recent Development
- 11.9 F. Hoffmann-La Roche Ltd.
- 11.9.1 F. Hoffmann-La Roche Ltd. Company Details
- 11.9.2 Company Business Overview
- 11.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Products Offered
- 11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
- 11.10 Gilead Sciences, Inc.
- 11.10.1 Gilead Sciences, Inc. Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Gilead Sciences, Inc. Indolent Lymphoma Treatment Products Offered
- 11.10.5 Gilead Sciences, Inc. Recent Development
- 11.11 Incyte Corporation
- 11.12 Infinity Pharmaceuticals, Inc.
- 11.13 Juno Therapeutics Inc.
- 11.14 MedImmune, LLC
12 Future Forecast
- 12.1 Indolent Lymphoma Treatment Market Forecast by Regions
- 12.1.1 Global Indolent Lymphoma Treatment Sales Forecast by Regions 2019-2025
- 12.1.2 Global Indolent Lymphoma Treatment Revenue Forecast by Regions 2019-2025
- 12.2 Indolent Lymphoma Treatment Market Forecast by Product
- 12.2.1 Global Indolent Lymphoma Treatment Sales Forecast by Product 2019-2025
- 12.2.2 Global Indolent Lymphoma Treatment Revenue Forecast by Product 2019-2025
- 12.3 Indolent Lymphoma Treatment Market Forecast by End User
- 12.4 North America Indolent Lymphoma Treatment Forecast
- 12.5 Europe Indolent Lymphoma Treatment Forecast
- 12.6 Asia Pacific Indolent Lymphoma Treatment Forecast
- 12.7 Central & South America Indolent Lymphoma Treatment Forecast
- 12.8 Middle East and Africa Indolent Lymphoma Treatment Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Indolent Lymphoma Treatment Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Indolent Lymphoma Treatment . Industry analysis & Market Report on Indolent Lymphoma Treatment is a syndicated market report, published as Global Indolent Lymphoma Treatment Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Indolent Lymphoma Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
